Plain-English translation of NCT06698887 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →This is a safety follow-up study for people in Korea who received , a type of blood cell therapy, as part of a larger research trial (KarMMa-9). The study tracks how these participants are doing over time after receiving the medication to make sure there are no delayed or long-term side effects.
Even after a treatment works in a trial, researchers need to follow patients over many years to catch any long-term side effects that might develop later. This medication is relatively new, so tracking its long-term safety in real-world use is important for patient safety.
You likely qualify if…
You likely don't qualify if…
As a participant, you would continue to be monitored by the research team to check on your health and safety after receiving the medication. This likely involves periodic check-ins, health assessments, and sharing information about how you are feeling and any health changes you experience. The study is designed to be a long-term safety watch, so you may be contacted periodically over months or years.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
South Korea